Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.

Ko JC, Tsai MS, Kuo YH, Chiu YF, Weng SH, Su YC, Lin YW.

Biochem Pharmacol. 2011 Mar 1;81(5):680-90. doi: 10.1016/j.bcp.2010.12.008.

PMID:
21168393
2.
3.

Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells.

Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Lin YW.

Biochem Pharmacol. 2010 Feb 15;79(4):655-64. doi: 10.1016/j.bcp.2009.09.024.

PMID:
19799875
4.

Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.

Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, Lin YW.

Exp Cell Res. 2009 Sep 10;315(15):2658-72. doi: 10.1016/j.yexcr.2009.06.002.

PMID:
19505457
5.

Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.

Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.

Lung Cancer. 2010 Aug;69(2):155-64. doi: 10.1016/j.lungcan.2009.10.013.

PMID:
19962780
6.

Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).

Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.

Mol Pharmacol. 2011 Jul;80(1):136-46. doi: 10.1124/mol.111.071316.

7.

Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.

Ko JC, Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.

Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012.

PMID:
21810436
8.

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.

Ko JC, Ciou SC, Cheng CM, Wang LH, Hong JH, Jheng MY, Ling ST, Lin YW.

Carcinogenesis. 2008 Jul;29(7):1448-58. doi: 10.1093/carcin/bgn130.

PMID:
18544565
9.

Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.

Tsai MS, Kuo YH, Chiu YF, Su YC, Lin YW.

J Pharmacol Exp Ther. 2010 Dec;335(3):830-40. doi: 10.1124/jpet.110.173146.

10.
11.

Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.

Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, Lin ST, Chang CC, Lin YW.

Mol Cancer Res. 2009 Aug;7(8):1378-89. doi: 10.1158/1541-7786.MCR-09-0051.

12.

Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells.

Ko JC, Huang YC, Chen HJ, Tseng SC, Chiu HC, Wo TY, Huang YJ, Weng SH, Chiou RY, Lin YW.

Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):56-65. doi: 10.1111/bcpt.12052.

13.

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.

Ko JC, Hong JH, Wang LH, Cheng CM, Ciou SC, Lin ST, Jheng MY, Lin YW.

Mol Cancer Ther. 2008 Nov;7(11):3632-41. doi: 10.1158/1535-7163.MCT-08-0578.

14.

Enhancement of mitomycin C-induced cytotoxicity by curcumin results from down-regulation of MKK1/2-ERK1/2-mediated thymidine phosphorylase expression.

Weng SH, Tsai MS, Chiu YF, Kuo YH, Chen HJ, Lin YW.

Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):298-306. doi: 10.1111/j.1742-7843.2011.00806.x.

15.

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.

Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.

Regul Toxicol Pharmacol. 2012 Dec;64(3):415-24. doi: 10.1016/j.yrtph.2012.10.003.

PMID:
23069143
16.
17.

Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.

Weng SH, Tseng SC, Huang YC, Chen HJ, Lin YW.

Biochem Pharmacol. 2012 Jul 1;84(1):126-36. doi: 10.1016/j.bcp.2012.03.011.

PMID:
22480737
18.

Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.

Zhang SH, Zhang H, He HW, Li L, Li XQ, Zhang YP, Shao RG.

Cancer Chemother Pharmacol. 2013 Oct;72(4):777-88. doi: 10.1007/s00280-013-2253-3.

PMID:
23975242
19.

Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.

Ko JC, Wang TJ, Chang PY, Syu JJ, Chen JC, Chen CY, Jian YT, Jian YJ, Zheng HY, Chen WC, Lin YW.

Biochem Pharmacol. 2015 Oct 1;97(3):331-40. doi: 10.1016/j.bcp.2015.07.025.

PMID:
26212550
20.

Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.

Puppin C, Puglisi F, Pandolfi M, Di Loreto C, Damante G.

Oncol Rep. 2011 Aug;26(2):309-14. doi: 10.3892/or.2011.1310.

PMID:
21617864

Supplemental Content

Support Center